Here are three quick points:
1. Jeffries analysts reiterated their “buy” rating for NuVasive stock with a price target of $72, on July 27.
2. Barclays analysts reiterated their “overweight” rating for NuVasive shares with a price target of $71, on July 27.
3. On July 27, Brean Capital analysts reiterated their “buy” rating for NuVasive stock with a price target of $70.
More articles on devices:
DePuy Synthes, Acumed, Stryker market leaders in Japan device market: 5 takeaways
Medical device makers pivot towards value-based care: 7 thoughts
Orthogrid Systems offering outpatient and short-stay total joint surgeons complete control: 4 thoughts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
